Laurus Labs Ltd - 540222 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meetings on June 12-13, 2024 Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
B&K Securities 14th Annual Conference - Trinity India 2024 on May 30, 2024 Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of ESOPs Laurus Labs Ltd - 540222 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report FY 2024 Laurus Labs Ltd - 540222 - Reply To The Clarification Sought By The Exchanges
Reply letter is attached Laurus Labs Ltd - 540222 - Clarification sought from Laurus Labs Ltd
The Exchange has sought Clarification from Laurus Labs Ltd with reference to the media report appearing on https://timesofindia.indiatimes.com dated May 25, 2024 (Link: https://timesofindia.indiatimes.com/city/hyderabad/laurus-labs-receives-usfda-letter-for-cgmp-violations/articleshow/110408394.cms) titled "Laurus Labs gets USFDA letter for CGMP violations".The reply is awaited. Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 FY 24 Concall transcript
Laurus Labs Strategically Focused On Talent Acquisition And Programme Advancement, Says CEO Chava
Laurus Labs consolidated net profit declined 28.73% in the fourth quarter of financial year 2024, and it missed analysts' estimates.
Laurus Labs Q4 Results Review - Product Mix, Reduced Operating Leverage Hurt Profitability: Motilal Oswal
Benefits from investments made over FY22-24 to gain momentum